SS-31 vs PNC-27: Mechanism, Half-Life & Research Use
When evaluating SS-31 vs PNC-27 for comparative biochemical studies, researchers are comparing two fundamentally distinct mechanistic classes of peptides. SS-31 (Elamipretide) is a targeted mitochondrial peptide that stabilizes cardiolipin and attenuates reactive oxygen species, whereas PNC-27 is a membrane-active peptide engineered to selectively bind HDM-2 on transformed cells and induce pore-mediated necrosis.
Quick answer
When evaluating SS-31 vs PNC-27 for comparative biochemical studies, researchers are comparing two fundamentally distinct mechanistic classes of peptides. SS-31 (Elamipretide) is a targeted mitochondrial peptide that stabilizes cardiolipin and attenuates reactive oxygen species, whereas PNC-27 is a membrane-active peptide engineered to selectively bind HDM-2 on transformed cells and induce pore-mediated necrosis.
Key takeaways
- In cellular biology and oncology research, [SS-31](/research-peptides/ss-31) and PNC-27 serve radically different experimental roles.
- To assist laboratory principal investigators in selecting the appropriate molecule for specific assay designs, the fundamental parameters of both compounds are contrasted below:
- The molecular architecture of the [SS-31 research peptide](/product/ss-31) allows it to cross cell membranes freely despite carrying a net positive charge at physiological pH.
- PNC-27 was designed to exploit specific surface protein alterations unique to malignant transformation.
Direct Structural and Functional Comparison
In cellular biology and oncology research, SS-31 and PNC-27 serve radically different experimental roles. While both are synthesized peptide sequences investigated in disease models, their molecular targets, subcellular localization patterns, and primary biophysical mechanisms diverge completely.
SS-31 (also designated as Elamipretide or MTP-131) is a small, cell-permeable tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) engineered to selectively localize to the inner mitochondrial membrane (IMM). Its primary mode of action centers on electrostatic interactions with cardiolipin, an essential phospholipid governing mitochondrial cristae structure and electron transport chain complex assembly. By stabilizing cardiolipin, SS-31 reduces mitochondrial oxidative stress, preserves ATP synthesis, and prevents pathological permeability transition pore opening.
In contrast, PNC-27 is a chimeric research peptide comprising an HDM-2-binding domain (residues 12–26 of p53) coupled to a cell-penetrating transmembrane signal sequence (penetratin). PNC-27 functions as a membrane-active anticancer peptide. Preclinical studies suggest that PNC-27 acts by selectively binding to membrane-bound HDM-2 proteins present on cancer cells, subsequently inserting into the cell membrane to form lethal transmembrane pores. This action induces rapid membrane disruption and necrosis in transformed cell lines while sparing non-transformed cell lines that lack surface HDM-2 expressions.
Physicochemical and Experimental Parameters Table
To assist laboratory principal investigators in selecting the appropriate molecule for specific assay designs, the fundamental parameters of both compounds are contrasted below:
| Criteria | SS-31 (Elamipretide) | PNC-27 | | :--- | :--- | :--- | | **Primary Target** | Cardiolipin (Inner Mitochondrial Membrane) | Membrane-bound HDM-2 protein | | **Mechanistic Class** | Mitochondrial cardiolipin stabilizer / antioxidant | Membrane-active cytolytic / pore-forming peptide | | **Primary Subcellular Site** | Inner Mitochondrial Membrane (IMM) | Outer Plasma Membrane | | **Reported In Vitro Half-Life** | ~2 to 4 hours (cell culture media) | ~1 to 3 hours (serum-containing media) | | **Solubility Profile** | Highly water-soluble (aqueous buffers/PBS) | Soluble in DMSO, sterile water, or dilute saline | | **Typical Preclinical Models** | Ischemia-reperfusion, bioenergetics, oxidative stress models | In vitro cancer cell viability, membrane lysis, xenograft models | | **Cell Death Pathway Target** | Inhibits apoptotic signaling & ROS-mediated collapse | Induces p53-independent necrotic cell lysis | | **Vial Sizes Available** | 10mg, 50mg lyophilized powder | 10mg, 50mg lyophilized powder |
Understanding these baseline criteria helps researchers establish appropriate control parameters, dosing protocols in vitro, and downstream detection methods.
SS-31: Molecular Mechanism and Cardiolipin Interaction
The molecular architecture of the SS-31 research peptide allows it to cross cell membranes freely despite carrying a net positive charge at physiological pH. Once inside the cell, SS-31 concentrates several hundred-fold in the inner mitochondrial membrane due to its affinity for cardiolipin, a tetra-acylglycerol phospholipid unique to mitochondrial membranes.
Under conditions of physiological stress or electron transport chain inefficiency, cardiolipin undergoes peroxidation by cytochrome c, leading to structural degradation of the IMM, dissolution of respiratory supercomplexes (respirasomes), and elevated generation of reactive oxygen species (ROS). Preclinical research indicates that SS-31 binds reversibly to cardiolipin via a combination of electrostatic and hydrophobic interactions.
By occupying the cardiolipin headgroup domain, SS-31 inhibits cytochrome c peroxidase activity, preventing cardiolipin oxidation. Consequently, IMM cristae geometry is maintained, electron transfer between Complex I, III, and IV is optimized, and uncoupled ROS production is minimized. These properties make SS-31 an essential standard in assays probing mitochondrial dysfunction, cardiotoxicity, and cellular ischemia.
PNC-27: HDM-2 Binding and Transmembrane Pore Formation
PNC-27 was designed to exploit specific surface protein alterations unique to malignant transformation. Grounding preclinical facts establish that PNC-27 functions as a membrane-active anticancer peptide. It is investigated for selectively binding membrane-bound HDM-2 on cancer cells and inducing necrosis through transmembrane pore formation, independent of the p53 pathway.
While HDM-2 (human double minute 2) is conventionally recognized as an intracellular E3 ubiquitin ligase that regulates cytosolic p53 degradation, transformed cells frequently express HDM-2 on their outer plasma membranes. The N-terminal residues of PNC-27 contain the p53-derived sequence that selectively docks onto this membrane-bound HDM-2 target.
Upon docking, the hydrophobic transmembrane domain of PNC-27 inserts into the lipid bilayer. Biophysical studies using high-resolution electron microscopy and lipid bilayer conductometry show that multiple PNC-27 molecules oligomerize within the cancer cell membrane, forming pore structures measuring several nanometers in diameter. This pore formation causes rapid extracellular calcium influx, loss of membrane potential, cellular swelling, and necrotic lysis—all occurring rapidly without requiring endogenous p53 activation or classic apoptotic caspase cascades.
In Vitro and Animal Literature: SS-31 in Bioenergetic Research
The preclinical literature evaluating SS-31 spans diverse disease models centered on metabolic collapse and oxidative damage. In rodent models of renal and myocardial ischemia-reperfusion injury, administration of SS-31 prior to or during reperfusion significantly diminished microvascular damage, reduced ATP depletion, and preserved organ function.
In cell culture models of neurodegeneration, cultured neuronal lines treated with mitochondrial toxins (such as MPP+ or rotenone) exhibited maintained mitochondrial membrane potential ($$\Delta\Psi_m$$) when co-treated with SS-31. Researchers frequently utilize SS-31 in Seahorse XF flux analyzer experiments to measure oxygen consumption rate (OCR) and extracellular acidification rate (ECAR), demonstrating its capacity to restore maximal respiration in stressed cells.
For additional scientific background regarding mitochondrial targeted peptides and related research models, explore our published papers in the PX1 Research Library.
Preclinical Literature: PNC-27 in Oncolytic Cytotoxicity Models
Preclinical evaluation of PNC-27 focuses primarily on in vitro cytotoxicity screens against panel arrays of human tumor cell lines, including pancreatic carcinoma, melanoma, osteosarcoma, and leukemia line variants. In these assays, PNC-27 demonstrates swift cytotoxic kinetic profiles, frequently achieving total cell lysis within 15 to 60 minutes of exposure.
A key observation across these preclinical trials is the differential susceptibility between malignant and non-malignant control cells. Fibroblasts, untransformed epithelial lines, and normal blood cells—which lack detectable surface HDM-2—show no significant pore formation or loss of cell viability when exposed to equivalent concentrations of PNC-27.
Furthermore, because the mechanism bypasses the internal p53 transcriptional machinery, PNC-27 maintains equal lytic efficacy in p53-mutated, p53-null, and p53-wildtype cancer cell lines. This distinguishes it from conventional chemotherapeutic agents that rely on intact apoptotic signaling pathways.
Selecting SS-31 vs PNC-27 for Specific Experimental Designs
Choosing between SS-31 and PNC-27 depends entirely on the biological primary endpoints of the planned experiment. The two compounds are non-interchangeable and address separate cellular compartments:
**Select SS-31 if the study design aims to:** - Protect or stabilize mitochondrial respiratory function under hypoxic, ischemic, or metabolic stress conditions. - Measure changes in mitochondrial ROS production, cardiolipin preservation, or cristae structural integrity. - Assess cytoprotection and bioenergetic rescue in non-oncological disease models.
**Select PNC-27 if the study design aims to:** - Investigate targeted outer membrane lysis in transformed vs non-transformed cell cultures. - Target surface HDM-2 receptor dynamics and subsequent pore-formation mechanics. - Evaluate p53-independent necrotic death mechanisms in chemotherapy-resistant cancer cell lines.
Related Compounds in Cytoprotective and Oncolytic Research
When designing comprehensive comparative studies, researchers often evaluate SS-31 or PNC-27 alongside other well-characterized peptide compounds within the same functional categories.
In mitochondrial and metabolic research, SS-31 is frequently compared against mitochondrial-derived peptides such as MOTS-c and Humanin, which act through distinct nuclear and cytosolic signaling pathways to regulate metabolic homeostasis and cellular survival during stress. In targeted cell-cycle and senolytic studies, peptides like FOXO4-DRI are studied for their ability to modulate apoptotic signaling selectively in senescent populations.
Investigators interested in viewing our complete line of high-purity laboratory compounds can browse the comprehensive catalog of research peptides available from PX1 Research.
Reconstitution, Laboratory Handling, and Storage Guidelines
Both SS-31 and PNC-27 are provided as lyophilized (freeze-dried) sterile powders to ensure long-term physical and chemical stability during transport and storage.
To reconstitute these peptides for laboratory use, allow the vial to reach room temperature before removing the seal to minimize moisture condensation. Reconstitute using laboratory-grade sterile bacteriostatic water or phosphate-buffered saline (PBS), depending on downstream assay compatibility. Gentle swirling is recommended; avoid vigorous vortexing to prevent peptide shear or foaming.
To calculate exact solvent volumes, molecular weights, and final working concentrations for in vitro assays, utilize the PX1 laboratory reconstitution calculator. Reconstituted stock solutions should be aliquoted into single-use polypropylene tubes and stored at -20°C or -80°C to avoid freeze-thaw degradation cycles.
Quality Verification and PX1 Research Standards
Experimental reproducibility in preclinical research depends strictly on compound purity, correct peptide sequence identity, and the absence of cytotoxic contaminants such as bacterial endotoxins.
PX1 Research manufactures all research compounds in USA-based, GMP-compliant facilities under ISO 17025 accredited quality management systems. Every batch undergoes rigorous quality assurance, including High-Performance Liquid Chromatography (HPLC) to confirm peptide purity ($$\ge 98\%$$) and Mass Spectrometry (MS) to verify precise molecular weight.
Additionally, every lot is subjected to Chromogenic LAL testing to guarantee endotoxin levels remain strictly below < 0.1 EU/mg, preventing confounding inflammatory artifacts in cell culture models. Researchers can view and download a batch-specific certificate of analysis directly from our portal prior to study initiation. For high-volume institutional studies or custom synthesis requirements, principal investigators can establish a direct lab account via our wholesale portal.
Frequently Asked Questions
What is the key functional difference between SS-31 and PNC-27?
SS-31 is a mitochondrial cardiolipin-binding peptide that preserves energy production and reduces ROS in stressed cells. PNC-27 is a membrane-active anticancer peptide that selectively binds surface HDM-2 on cancer cells to form lethal membrane pores and induce necrosis.
Does PNC-27 require an intact p53 pathway to exert its effects?
No. Preclinical research demonstrates that PNC-27 induces pore formation and membrane lysis independent of the intracellular p53 pathway, making it effective in p53-null and p53-mutated cancer cell models.
How does SS-31 target the mitochondria?
SS-31 contains a structural motifs (D-Arg-Dmt-Lys-Phe-NH2) that allows it to cross cell membranes freely and selectively concentrate at the inner mitochondrial membrane, where it electrostatically binds to cardiolipin.
What solvent should be used to reconstitute SS-31 and PNC-27?
SS-31 is highly water-soluble and reconstitutes readily in sterile water or standard PBS. PNC-27 dissolves in sterile water, saline, or dilute DMSO depending on the required concentration and assay protocol.
Are SS-31 and PNC-27 intended for human clinical use?
No. SS-31 and PNC-27 supplied by PX1 Research are strictly intended for in vitro laboratory research and preclinical animal studies. They are not for human or veterinary use.
How are PX1 Research peptides tested for purity?
Every lot undergoes HPLC and Mass Spectrometry testing in an ISO 17025 accredited laboratory to verify sequence identity and ensure purity levels meet or exceed 98%.
What are the endotoxin limits for PX1 research peptides?
PX1 Research enforces strict endotoxin controls, verifying that levels are kept below 0.1 EU/mg via Chromogenic LAL assays to prevent interference in cellular and animal models.
How should reconstituted peptide stock solutions be stored?
Reconstituted stocks should be aliquoted into single-use polypropylene tubes and stored at -20°C or -80°C. Repeated freeze-thaw cycles must be avoided to prevent peptide degradation.
Related pages
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.